Senores Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, has announced a significant investment of $2 million (approximately ₹16.6 crore) in its wholly owned US subsidiary, Senores Pharmaceuticals Inc. (SPI). This strategic move aligns with the company's commitment to strengthening its presence in the American market and supporting its overseas operations.

Investment Details

The investment, made through a rights issue, involves the acquisition of 120,480 equity shares at $16.60 per share, totaling $1,999,968. This capital injection is part of Senores Pharmaceuticals' planned utilization of its Initial Public Offer (IPO) proceeds, as outlined in the company's prospectus dated December 24, 2024.

About Senores Pharmaceuticals Inc.

Senores Pharmaceuticals Inc., incorporated on January 28, 2021, plays a crucial role in the parent company's US operations. SPI is responsible for:

• Holding intellectual properties used by Senores Pharmaceuticals
• Managing ANDA (Abbreviated New Drug Application) approvals
• Entering into agreements with marketing partners in the United States

Financial Performance

The US subsidiary has shown impressive growth over the past three years:

This consistent growth underscores the strategic importance of SPI to Senores Pharmaceuticals' global operations.

Regulatory Compliance

The company has confirmed that the investment complies with all necessary regulations, including:

• Approval under the Foreign Exchange Management Act, 1999
• Adherence to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Strategic Implications

This investment represents a significant step for Senores Pharmaceuticals in reinforcing its US market presence. By allocating capital to its American subsidiary, the company aims to:

1. Enhance working capital for US operations
2. Support the growth and expansion of its intellectual property portfolio
3. Strengthen relationships with marketing partners in the United States

The move is expected to contribute to Senores Pharmaceuticals' overall global strategy and potentially drive future growth in the competitive pharmaceutical market.

As the pharmaceutical landscape continues to evolve, Senores Pharmaceuticals' investment in its US subsidiary demonstrates its commitment to maintaining a strong foothold in one of the world's largest pharmaceutical markets.

Senores Pharmaceuticals Limited has announced the successful completion of its acquisition of 8,454 equity shares in Havix Group Inc., doing business as Aavis Pharmaceuticals. This marks the final step in a transaction that began in March 2025, as disclosed in a recent regulatory filing.

Acquisition Details

The acquisition was executed in two phases:

1. Direct Acquisition: Senores Pharmaceuticals directly acquired 7,914 shares of Havix Group Inc.
2. Subsidiary Acquisition: The remaining 540 shares were acquired through Senores Pharmaceuticals Inc., the company's wholly-owned US subsidiary.

Regulatory Compliance

The split acquisition strategy was necessitated by regulatory requirements from the Reserve Bank of India (RBI). The company had to obtain specific approvals for the acquisition of the final 540 shares through its US subsidiary, which explains the phased approach to the transaction.

Timeline of Events

• March 11 and 12, 2025: Initial intimations regarding the planned acquisition of 8,454 equity shares from certain public shareholders of Havix Group Inc.
• April 22 and June 23, 2025: Updates on the progress of the acquisition, noting that 7,914 shares had been acquired directly, with the remaining 540 shares pending due to RBI approval requirements.
• September 12, 2025: Final announcement of the completion of the acquisition, including the purchase of the remaining 540 shares through the US subsidiary.

Management Statement

Vinay Kumar Mishra, Company Secretary and Compliance Officer of Senores Pharmaceuticals Limited, confirmed the completion of the transaction in the regulatory filing, stating, "Upon acquisition of said 540 equity shares, the transaction of acquisition for 8,454 equity shares stands completed."

About Senores Pharmaceuticals Limited

Senores Pharmaceuticals Limited is headquartered in Ahmedabad, Gujarat, India. The company is listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). With this acquisition, Senores Pharmaceuticals has expanded its presence in the pharmaceutical sector, potentially strengthening its position in the market.

The completion of this acquisition marks a significant milestone for Senores Pharmaceuticals, potentially enhancing its product portfolio and market reach through the integration with Havix Group Inc., operating as Aavis Pharmaceuticals.